This partnership, which marks the entry of Biocon’s generic formulations into Latin America, builds upon a successful association with Libbs, which began in 2017 to launch biosimilar Trastuzumab in Brazil.
Original source: https://health.economictimes.indiatimes.com/news/pharma/81745520?utm_source=RSS&utm_medium=ETRSS
